Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:2:p8
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 2 (pt 8/16)
Character Range: 139191–142146

the maximum recommended daily dose is no greater than 400 micrograms, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
FOLIC ACID for human therapeutic use except:
 (a) when included in Schedule 4; or
 (b) in preparations containing 500 micrograms or less of folic acid per recommended daily dose.
FOLINIC ACID for human therapeutic use except:
 (a) when included in Schedule 4; or
 (b) in preparations containing 500 micrograms or less of folinic acid per recommended daily dose.
FORMALDEHYDE (excluding its derivatives) for human therapeutic use except:
 (a) in oral hygiene preparations containing 0.1% or less of free formaldehyde; or
 (b) in other preparations containing 0.2% or less of free formaldehyde.
GELSEMIUM SEMPERVIRENS.
GLUTARAL for human therapeutic use.
GUAIFENESIN in a modified release dosage form of 1200 mg or less of guaifenesin with a recommended daily dose of 2400 mg or less when not labelled for the treatment of children under 12 years of age.
HEXACHLOROPHENE in preparations for human use containing 3% or less of hexachlorophene except:
 (a) in preparations for use on infants, as specified in Schedule 4; or
 (b) in preparations for cosmetic use, as specified in Schedule 6; or
 (c) in other preparations containing 0.75% or less of hexachlorophene.
HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use:
 (a) for dermal use in preparations containing 0.5% or less of hydrocortisone, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or
 (b) for dermal use in preparations containing 1% or less of hydrocortisone, in packs containing 15 g or less of such preparations, containing an antifungal substance and no other therapeutically active constituent:

          (i) for the treatment of tinea (tinea pedis, tinea cruris, tinea corporis) and other fungal skin infections; and

          (ii) not labelled for the treatment of children under 12 years of age; or
 (c) for rectal use in preparations containing 0.5% or less of hydrocortisone, when combined with a local anaesthetic substance but no other therapeutically active constituent except unscheduled astringents:

          (i) in undivided preparations in packs of 35 g or less; or

          (ii) in packs containing 12 or less suppositories.
HYDROQUINONE (excluding monobenzone and alkyl ethers of hydroquinone included in Schedule 4) in preparations for human external therapeutic or cosmetic use containing 2% or less of hydroquinone except:
 (a) in hair preparations containing 0.3% or less of hydroquinone; or
 (b) in cosmetic nail preparations containing 0.02% or less of hydroquinone.
HYOSCINE:
 (a) for transdermal use in preparations containing 2 mg or less of total solanaceous alkaloids per dosage unit; or
 (b)